# Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT07214961** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ARTBIO Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer (CRPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** AB001

## Key facts

- **NCT ID:** NCT07214961
- **Lead sponsor:** ARTBIO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2027-11-03
- **Final completion:** 2028-11-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214961, "Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07214961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*